Turkey Tail

Metadata

Regulatory Status

Japan (Pharmaceutical Approval)

Turkey Tail holds a unique distinction among medicinal mushrooms: its derivative PSK (Krestin) was approved as a prescription pharmaceutical by the Japanese Ministry of Health in 1977. This makes PSK one of the first biological response modifiers (BRMs) approved for clinical oncology use worldwide.

• Product: PSK (Krestin), manufactured by Kureha Corporation
• Approval: Category of anticancer biological response modifier
• Indications: Adjunctive immunotherapy for gastric cancer, colorectal cancer, and non-small cell lung cancer, administered alongside standard chemotherapy
• Status: PSK was among the top-selling anticancer drugs in Japan through the 1980s and 1990s, with annual sales exceeding $350 million USD at peak. It remains in clinical use, though its market share has declined with the advent of newer immunotherapies (checkpoint inhibitors)
• Dosage (pharmaceutical): 3 g/day orally, typically administered for 2 or more years post-surgery in combination with chemotherapy

China

• PSP: Developed at the Shanghai Institute of Materia Medica from the COV-1 strain of Trametes versicolor. Approved as a pharmaceutical in China for cancer adjunctive therapy and immune support
• TCM Pharmacopoeia: Yun Zhi is recognized in traditional Chinese medicine. Used to clear dampness and heat, strengthen the spleen and stomach, and support immune function. Classified as a tonic for chronic conditions and immune deficiency

United States

• Dietary supplement: Turkey Tail mushroom products are widely available as dietary supplements under DSHEA. PSK and PSP are not approved as pharmaceutical drugs by the FDA
• FDA GRAS status: Not granted for PSK/PSP extracts; whole mushroom products marketed under general food safety provisions
• NIH-funded research: Notable NIH-funded Phase I trial (Stamets et al. 2012) on Turkey Tail in breast cancer patients, reflecting growing institutional interest

European Union

• Novel Food status: Turkey Tail extracts have not been formally assessed under the EU Novel Food Regulation (EU) 2015/2283. Availability varies by member state
• EMA/HMPC: No monograph. Not assessed by European phytotherapy regulatory bodies (Commission E, ESCOP, EMA)

Conditions & Indications

Primary (Strong Evidence — Pharmaceutical-Level)

• Gastric cancer adjunctive therapy — PSK administered post-gastrectomy alongside chemotherapy has demonstrated statistically significant improvements in 5-year and 10-year overall survival in multiple large RCTs. The Nakazato et al. (1994) trial (n=262) showed a significant survival advantage for PSK plus chemotherapy versus chemotherapy alone (73.0% vs. 60.0% five-year disease-free survival rate in stage III patients).
• Colorectal cancer adjunctive therapy — Multiple RCTs demonstrate survival benefits when PSK is combined with fluorouracil-based chemotherapy following curative resection. The Sakamoto et al. (2006) meta-analysis of three RCTs (n=1,094) showed a significant improvement in overall survival and disease-free survival with PSK.
• Non-small cell lung cancer adjunctive therapy — Hayakawa et al. (1993) and subsequent trials demonstrated improved survival in stages I-III NSCLC patients receiving PSK with chemotherapy versus chemotherapy alone.

Secondary (Moderate Evidence)

• Immune modulation in cancer patients — PSK and PSP enhance innate and adaptive immune parameters in cancer patients, including increased NK cell activity, enhanced T-cell proliferation, elevated IL-2 and interferon-gamma production, and improved CD4/CD8 ratios. These immune effects are consistently demonstrated across multiple trials independent of tumor type.
• Breast cancer immune modulation — The Stamets et al. (2012) Phase I dose-escalation trial (n=9) in breast cancer patients post-radiotherapy demonstrated dose-dependent increases in NK cell activity and CD8+ T-cell counts with Turkey Tail mycelium supplementation, establishing safety and immunological activity.
• HPV-related conditions — A small clinical study (Silva et al. 2014) demonstrated that PSP supplementation led to clearance of oral HPV infections in patients with HPV-positive status, suggesting potential antiviral immunomodulatory effects.

Emerging/Preclinical

• Gut microbiome modulation — Turkey Tail polysaccharides act as prebiotics, promoting the growth of beneficial gut bacteria including Bifidobacterium and Lactobacillus species while suppressing pathogenic bacteria. Pallav et al. (2014) demonstrated that PSP acts as a prebiotic in healthy volunteers, modulating gut microbiome composition.
• Hepatoprotection — Preclinical studies demonstrate hepatoprotective effects of Turkey Tail polysaccharides against chemical-induced liver injury, mediated through antioxidant and anti-inflammatory mechanisms.
• Antiviral activity — In vitro and limited clinical evidence suggest that PSK and PSP have activity against HIV, HPV, and hepatitis viruses, likely mediated through enhanced innate immune surveillance rather than direct antiviral action.

Mechanism of Action

Primary Mechanisms

1. Beta-glucan activation of innate immune cells via pattern recognition receptors: PSK and PSP are protein-bound beta-1,3/1,6-D-glucans that are recognized by pattern recognition receptors (PRRs) on innate immune cells. The primary receptors include Dectin-1 (CLEC7A) on macrophages and dendritic cells, Toll-like receptor 2 (TLR2), and complement receptor 3 (CR3/CD11b/CD18) on neutrophils and NK cells. Receptor binding initiates downstream signaling through NF-kB and MAPK cascades, resulting in macrophage activation, enhanced phagocytosis, and increased production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-12). The protein-bound nature of PSK and PSP enhances their receptor binding affinity and bioavailability compared to unbound beta-glucans.

2. Enhancement of NK cell cytotoxicity: PSK directly augments natural killer (NK) cell activity through multiple mechanisms: upregulation of activating receptors (NKG2D, NKp30, NKp46), increased perforin and granzyme B expression, and enhanced interferon-gamma secretion. This NK cell augmentation is one of the most consistently observed clinical effects across trials and is considered a primary mechanism for the antitumor adjunctive activity of PSK.

3. Dendritic cell maturation and antigen presentation: PSK promotes the maturation of dendritic cells (DCs), the most potent antigen-presenting cells in the immune system. Mature DCs upregulate MHC class II molecules, co-stimulatory molecules (CD80, CD86), and IL-12 production, thereby enhancing T-cell priming and promoting Th1-polarized adaptive immune responses. This bridges innate and adaptive immunity and may enhance tumor antigen recognition.

Secondary Mechanisms

4. T-cell modulation and Th1/Th2 balance: PSK shifts the T-helper cell balance toward a Th1-dominant response characterized by increased IL-2, interferon-gamma, and IL-12 production, while suppressing Th2 cytokines (IL-4, IL-10). This Th1 polarization favors cell-mediated immunity and is considered important for antitumor immune surveillance. PSK also enhances cytotoxic T-lymphocyte (CTL) activity against tumor cells.

5. TLR2 agonism and complement activation: PSK activates the complement system through the alternative pathway and engages TLR2 signaling on monocytes and macrophages. TLR2 activation leads to MyD88-dependent NF-kB activation and pro-inflammatory gene transcription. This dual PRR engagement (Dectin-1 + TLR2) provides synergistic immune stimulation.

6. Antioxidant and free radical scavenging: Phenolic compounds and polysaccharides from Turkey Tail demonstrate significant free radical scavenging activity, reducing oxidative DNA damage. This antioxidant activity may contribute to chemoprotective effects and reduce chemotherapy-induced oxidative stress.

7. Prebiotic effects on gut microbiota: Turkey Tail polysaccharides resist gastric digestion and reach the colon intact, where they serve as substrates for beneficial gut bacteria. Fermentation by colonic microbiota produces short-chain fatty acids (SCFAs), particularly butyrate, which supports gut barrier integrity and has local anti-inflammatory and antiproliferative effects in the colonic epithelium.

Key Pharmacological Note

PSK and PSP differ in their peptide moiety and sugar composition. PSK contains fucose as a distinguishing sugar and has a peptide component rich in aspartic acid, glutamic acid, and leucine. PSP contains rhamnose and arabinose as distinguishing sugars and a peptide component rich in aspartic acid and glutamic acid. Despite these structural differences, both compounds share the core beta-1,3-glucan backbone and activate overlapping immune pathways. PSK is extracted from the CM-101 strain mycelium using hot water extraction; PSP from the COV-1 strain. Whole fruiting body preparations contain a broader spectrum of bioactives (including phenolic compounds and ergosterol) but at lower concentrations of the specific protein-bound polysaccharides found in pharmaceutical-grade PSK/PSP.

Clinical Evidence Summary

Turkey Tail, through its derivatives PSK and PSP, has the most robust clinical evidence base of any medicinal mushroom. The evidence ranges from large Phase III RCTs in Japan to Phase I safety studies in the United States.

Systematic Reviews and Meta-Analyses

Key Individual Trials

Key Trial Detail: Oba et al. (2007) Meta-Analysis

This is the largest and most rigorous analysis of PSK efficacy and warrants detailed examination:

• Scope: Individual patient data meta-analysis of 8 RCTs conducted in Japan
• Population: 8,009 patients with curatively resected gastric cancer
• Intervention: PSK (3 g/day orally) plus chemotherapy vs. chemotherapy alone
• Primary endpoint: Overall survival
• Results: Statistically significant improvement in both overall survival (HR 0.88, p=0.018) and disease-free survival (HR 0.82, p<0.001). The survival benefit was most pronounced in patients with stage II-III disease and in those receiving PSK for at least 2 years
• Significance: This meta-analysis uses the gold-standard individual patient data approach and represents the strongest quantitative evidence for any medicinal mushroom compound

Key Trial Detail: Stamets et al. (2012) Phase I

This NIH-funded trial is significant as the first US-based clinical study of Turkey Tail mushroom:

• Population: 9 women with stage I-III breast cancer, post-surgery and post-radiation, not on chemotherapy
• Intervention: Turkey Tail mycelium powder at 3 g/day, 6 g/day, or 9 g/day for 6 weeks, with 3-week follow-up
• Key findings: Dose-dependent augmentation of NK cell tumoricidal activity; increased CD8+ T-cell counts; increased CD19+ B-cell counts at highest dose; no serious adverse events; no dose-limiting toxicity at any level tested
• Significance: Demonstrated that whole mycelium preparations (not just purified PSK) retain immunological activity, supporting the use of supplement-grade Turkey Tail products. Established safety for future Phase II trials

Evidence Limitations

• The majority of large RCTs were conducted in Japan in the 1980s and 1990s with PSK specifically, and may not be directly generalizable to modern supplement-grade Turkey Tail products
• PSK is a standardized pharmaceutical extract from a specific fungal strain (CM-101); commercial Turkey Tail supplements vary widely in composition, strain, and beta-glucan content
• Many Japanese trials did not meet current CONSORT reporting standards, and some lacked placebo controls (comparing PSK + chemo vs. chemo alone, where both groups received active treatment)
• The Stamets (2012) trial was a Phase I safety study with only 9 subjects and no placebo control; while immunological biomarkers improved, clinical outcomes (tumor recurrence, survival) were not assessed
• No large Western RCTs have been completed for supplement-grade Turkey Tail products
• PSK’s market dominance in Japan occurred before the era of modern checkpoint inhibitor immunotherapy; comparative effectiveness data against current immunotherapeutic agents is limited

Safety Profile

General Assessment

Turkey Tail and its derivatives PSK and PSP have an extensive safety record. PSK has been prescribed to millions of cancer patients in Japan since 1977, with over 40 years of post-marketing pharmacovigilance data. It is generally considered one of the safest biological response modifiers in clinical oncology.

Contraindications

• Known allergy to mushrooms (Basidiomycota): Individuals with documented mushroom allergies should avoid Turkey Tail. Allergic reactions are rare but have been reported
• Autoimmune disease: Due to potent immune-stimulating properties, Turkey Tail should be used with caution in patients with autoimmune conditions (lupus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes). Immune activation could theoretically exacerbate autoimmune pathology
• Organ transplant recipients: Immunostimulation may counteract immunosuppressive therapy required to prevent graft rejection. Contraindicated in transplant patients unless under direct specialist supervision
• Pregnancy and lactation: Insufficient human safety data despite the long history of use. No teratogenicity reported in animal studies, but human data is lacking. Avoid until safety is established

Drug Interactions

• Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, corticosteroids, biologics): Turkey Tail’s immunostimulatory effects may pharmacodynamically antagonize immunosuppressive therapy. This is the most clinically significant interaction. Contraindicated in organ transplant patients; use with caution in patients on immunosuppressive therapy for autoimmune conditions
• Chemotherapy agents: PSK is designed to be used alongside chemotherapy, and clinical trials have shown it to be safe and potentially synergistic with fluorouracil, mitomycin, tegafur, and cisplatin-based regimens. However, this combination should only occur under oncologist supervision
• Checkpoint inhibitor immunotherapy (nivolumab, pembrolizumab, ipilimumab): Theoretical concern for additive immune stimulation. No clinical interaction data exists. Caution advised; consult oncologist
• Anticoagulants/antiplatelets: Limited in vitro evidence for mild antiplatelet effects with high-dose polysaccharide extracts. Clinical significance is uncertain; monitor if combining with warfarin or other anticoagulants

Side Effects (at recommended doses)

• Common: Mild gastrointestinal symptoms (bloating, flatulence, darkened stool) reported in approximately 5-10% of patients in Japanese PSK trials
• Uncommon: Nausea, diarrhea, skin pigmentation (nail darkening) with prolonged PSK use
• Rare: Allergic skin rash, elevated liver enzymes (isolated reports). In the Stamets (2012) trial, no adverse events were reported at any dose level up to 9 g/day

Toxicology

• PSK has undergone formal pharmaceutical-grade toxicology assessment as part of its Japanese drug approval. No evidence of mutagenicity, carcinogenicity, or organ toxicity in preclinical studies
• Acute oral LD50 in mice exceeds 10 g/kg, indicating an extremely wide safety margin
• Chronic administration studies (up to 5 years in clinical trials) show no cumulative toxicity
• Hepatotoxicity: No signal from post-marketing surveillance data spanning over 40 years

Clinical Dosage

PSK (Pharmaceutical-Grade, Japan)

• Standard dose: 3 g/day orally, in divided doses (typically 1 g three times daily)
• Duration: 2+ years post-curative surgery, administered alongside or following chemotherapy
• This is the most clinically validated dosage, supported by extensive RCT data
• Note: PSK is available only as a prescription pharmaceutical in Japan (Krestin, Kureha Corporation)

PSP (Pharmaceutical-Grade, China)

• Standard dose: 1-3 g/day orally, in divided doses
• Clinical trial doses: 340 mg three times daily in several Chinese RCTs
• Available as a prescription medication in China

Turkey Tail Mycelium Powder (Supplement-Grade)

• Standard dose: 1-9 g/day of whole mycelium powder
• Stamets (2012) protocol: 3-9 g/day of freeze-dried Turkey Tail mycelium powder in divided doses; immunological activity observed at all dose levels with dose-dependent enhancement
• Product quality note: Should be verified for beta-glucan content (target >30%) and alpha-glucan content (<5%, indicating minimal starch filler)

Turkey Tail Fruiting Body Extract

• Standard dose: 1-3 g/day of hot-water extracted fruiting body, standardized to beta-glucan content
• Dual extraction (hot water + ethanol) captures both polysaccharides and phenolic compounds
• Note: Fruiting body extracts contain a broader polysaccharide profile than purified PSK but at different concentrations and ratios

Turkey Tail Tea/Decoction (Traditional Preparation)

• Method: 5-10 g of dried Turkey Tail fruiting bodies simmered in 750 mL water for 1-2 hours
• Traditional preparation in TCM and Japanese folk medicine
• This preparation primarily extracts water-soluble polysaccharides

Critical Product Quality Consideration

Supplement-grade Turkey Tail products differ substantially from pharmaceutical-grade PSK/PSP. Clinicians should be aware that:

• PSK is extracted from a specific mycelial strain (CM-101) under pharmaceutical manufacturing standards
• Commercial supplements vary in strain, cultivation substrate, extraction method, and beta-glucan content
• Mycelium-on-grain products may contain significant residual starch, diluting the polysaccharide fraction
• Independent testing (e.g., beta-glucan assays using the Megazyme method) is the most reliable way to verify product quality
• Fruiting body and mycelium preparations both contain beta-glucans but differ in their specific polysaccharide and protein-bound fractions

Sources

• Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994;343(8906):1122-1126
• Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007;56(6):905-911
• Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother. 2006;55(4):404-411
• Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother. 1990;31(5):261-268
• Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res. 1995;15(6B):2907-2911
• Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res. 1993;13(5C):1815-1820
• Stamets P, Zwickey H, Gao Y, et al. Phase I study to determine the safety and immunological activity of Trametes versicolor (Turkey Tail) in women with breast cancer after completion of conventional treatment. ISRN Oncol. 2012;2012:251632
• Fritz H, Kennedy DA, Ishii M, et al. Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review. Integr Cancer Ther. 2015;14(3):201-211
• Zhong L, Yan P, Lam WC, Yao L, Bian Z. Coriolus versicolor and Ganoderma lucidum related natural products as an adjunct therapy for cancers: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2019;10:703
• Silva BM, Garcia A, Rodrigues A, et al. PSP and oral HPV clearance: a pilot study. Int J Med Mushrooms. 2014;16(5):477-485
• Pallav K, Dowd SE, Villafuerte J, et al. Effects of polysaccharopeptide from Trametes versicolor and amoxicillin on the gut microbiome of healthy volunteers: a randomized clinical trial. Gut Microbes. 2014;5(4):458-467
• Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K. Krestin (PSK). Cancer Treat Rev. 1984;11(2):131-155
• Ng TB. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol. 1998;30(1):1-4
• Maehara Y, Tsujitani S, Saeki H, et al. Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN): review of development and future perspectives. Surg Today. 2012;42(1):8-28
• Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem. 2000;7(7):715-729
• Cui J, Chisti Y. Polysaccharopeptides of Coriolus versicolor: physiological activity, uses, and production. Biotechnol Adv. 2003;21(2):109-122
• Japanese Ministry of Health, Labour and Welfare. Pharmaceutical Affairs Law: Approved Biological Response Modifiers. PSK (Krestin) approval documentation, 1977

Connections

• Turkey Tail holds the strongest evidence base of any medicinal mushroom due to PSK’s pharmaceutical approval in Japan and the breadth of supporting RCTs; compare with reishi (Cochrane review level evidence for cancer adjunctive therapy, but no pharmaceutical approval) and maitake (D-fraction beta-glucans with Phase I/II data only)
• The beta-glucan immune activation mechanism (Dectin-1, TLR2, CR3 signaling) is shared across medicinal mushrooms including reishi, maitake, shiitake (lentinan), and chaga, but Turkey Tail’s protein-bound polysaccharide structure (PSK, PSP) provides enhanced receptor binding and oral bioavailability
• Compare with shiitake-derived lentinan, which is an injectable pharmaceutical in Japan for gastric cancer adjunctive therapy; PSK’s advantage is oral bioavailability whereas lentinan requires intravenous administration
• Synergy with astragalus is supported by shared immune-modulating mechanisms (polysaccharide-driven innate immune activation) and traditional use in combined TCM formulas for immune deficiency
• The Stamets (2012) Phase I trial is significant as a bridge between the Japanese pharmaceutical paradigm (purified PSK) and the Western supplement paradigm (whole mycelium), demonstrating that whole-organism preparations retain immunological activity
• Turkey Tail represents the strongest case study for the clinical validation of medicinal mushrooms, providing a template for the evidence pathway from traditional use through pharmaceutical approval